Identification and optimisation of a pyrimidopyridone series of IRAK4 inhibitors.

Autor: Cumming IA; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom. Electronic address: iain.cumming@astrazeneca.com., Degorce SL; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Aagaard A; Discovery Sciences, R&D, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden., Braybrooke EL; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Davies NL; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Diène CR; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Eatherton AJ; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Felstead HR; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Groombridge SD; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Lenz EM; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Li Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176 PR China., Nai Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176 PR China., Pearson S; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Robb GR; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Scott JS; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Steward OR; Medicinal Chemistry, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge Science Park, Unit 310 Darwin Building, Cambridge CB4 0WG, United Kingdom., Wu C; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176 PR China., Xue Y; Discovery Sciences, R&D, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden., Zhang L; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176 PR China., Zhang Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176 PR China.

Publikováno v: Bioorganic & medicinal chemistry [Bioorg Med Chem] 2022 Jun 01; Vol. 63, pp. 116729. Date of Electronic Publication: 2022 Apr 02.

Lowering Lipophilicity by Adding Carbon: One-Carbon Bridges of Morpholines and Piperazines.

Autor: Degorce SL; Medicinal Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, Unit 310 Darwin Building , Cambridge CB4 0WG , United Kingdom., Bodnarchuk MS; Medicinal Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, Unit 310 Darwin Building , Cambridge CB4 0WG , United Kingdom., Cumming IA; Medicinal Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, Unit 310 Darwin Building , Cambridge CB4 0WG , United Kingdom., Scott JS; Medicinal Chemistry, Oncology, IMED Biotech Unit , AstraZeneca , Cambridge Science Park, Unit 310 Darwin Building , Cambridge CB4 0WG , United Kingdom.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2018 Oct 11; Vol. 61 (19), pp. 8934-8943. Date of Electronic Publication: 2018 Sep 20.

Structure-Based Design of Potent and Selective Inhibitors of the Metabolic Kinase PFKFB3.

Autor: Boyd S; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Brookfield JL; ‡CRT Discovery Laboratories, Jonas Webb Building (B910), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom., Critchlow SE; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Cumming IA; ‡CRT Discovery Laboratories, Jonas Webb Building (B910), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom., Curtis NJ; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Debreczeni J; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Degorce SL; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Donald C; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Evans NJ; §CRT Discovery Laboratories, Wolfson Institute for Biomedical Research, University College London, The Cruciform Building, Gower Street, London WC1E 6BT, United Kingdom., Groombridge S; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Hopcroft P; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Jones NP; §CRT Discovery Laboratories, Wolfson Institute for Biomedical Research, University College London, The Cruciform Building, Gower Street, London WC1E 6BT, United Kingdom., Kettle JG; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Lamont S; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Lewis HJ; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., MacFaull P; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., McLoughlin SB; ‡CRT Discovery Laboratories, Jonas Webb Building (B910), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom., Rigoreau LJ; ‡CRT Discovery Laboratories, Jonas Webb Building (B910), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom., Smith JM; ‡CRT Discovery Laboratories, Jonas Webb Building (B910), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom., St-Gallay S; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Stock JK; §CRT Discovery Laboratories, Wolfson Institute for Biomedical Research, University College London, The Cruciform Building, Gower Street, London WC1E 6BT, United Kingdom., Turnbull AP; §CRT Discovery Laboratories, Wolfson Institute for Biomedical Research, University College London, The Cruciform Building, Gower Street, London WC1E 6BT, United Kingdom., Wheatley ER; §CRT Discovery Laboratories, Wolfson Institute for Biomedical Research, University College London, The Cruciform Building, Gower Street, London WC1E 6BT, United Kingdom., Winter J; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom., Wingfield J; †Oncology Innovative Medicines Unit, AstraZeneca, 35S47 Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2015 Apr 23; Vol. 58 (8), pp. 3611-25. Date of Electronic Publication: 2015 Apr 13.

STEROID HORMONE REQUIREMENTS FOR THE MAINTENANCE OF EARLY PREGNANCY IN SHEEP: A STUDY USING OVARIECTOMIZED ADRENALECTOMIZED EWES

Autor: R. Baxter, R. A. S. Lawson, Cumming Ia

Publikováno v: Reproduction. 40:443-446

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a05ba04f27b3f603465bbb263ff788ab
https://doi.org/10.1530/jrf.0.0400443

A novel series of positive modulators of the AMPA receptor: structure-based lead optimization.

Autor: Jamieson C; Merck Research Laboratories, MSD, Newhouse, Motherwell, Lanarkshire, UK. craig.jamieson@strath.ac.uk, Campbell RA, Cumming IA, Gillen KJ, Gillespie J, Kazemier B, Kiczun M, Lamont Y, Lyons AJ, Maclean JK, Martin F, Moir EM, Morrow JA, Pantling J, Rankovic Z, Smith L

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2010 Oct 15; Vol. 20 (20), pp. 6072-5. Date of Electronic Publication: 2010 Aug 15.